On Oct 23, HBM Holdings-B (02142.HK) announced that batoclimab injection (Enlida) has been approved by China's NMPA for generalized myasthenia gravis, the company's first approved product, on which it retains tiered royalties in Greater China. Included in the Stock Connect on Sept 7, its southbound stake rose from 2.10% on the first effective day to 13.24% on Oct 23, or 119.81 million shares worth about HK$1.23 billion.
WENGE AI (01956.HK) closed at HKD 59.10 on October 23, 2026, down 4.98% for the day. The company's shares were included in the Hang Seng Composite Index with effect from September 7, 2026 and were accordingly added to Stock Connect, and the share price has fallen about 34.26% since inclusion.
LC HOLDING (02490.HK) fell 0.36% to HKD 4.140 on Oct 26; Liu Family Trust holds shares via Lecang Flourishing; Trident Trust at 32.60%; interim profit up 42.9%.
YIDU TECH (02158.HK) traded at HKD 2.915 intraday on Oct 26, up 1.22%, down 23.1% since its removal from Stock Connect on Sept 7; FY2026 revenue rose 14.6%.
On October 26, 2026, XPENG-W (09868.HK) weakened. As of 14:00, it was quoted at HK$35.78, down 3.61%.
Hong Kong indices fell this week, with the HSI down 4.52% and the HSTECH down 5.76%, while southbound outflows reached HK$17.046 billion over four sessions.
HUA HONG GRACE (01347.HK) fell 4.45% to HKD 64.450; 8-inch wafer capacity will shrink 2.4% in 2026 as AI server power demand surges, and Q3 lands 5 November.
EXELLAND ROBOT (03231.HK) fell 1.04% to HKD 34.400; Zhejiang service robot output rose 91.0% in Q1-Q3, and Agibot set a Guinness record with 110 robots.
On October 26, 2026, CSRC issued a filing notice to Rayson HI-TECH for its HK listing and full circulation of 102.16 million shares held by 40 shareholders.
Recent listings fell in the week to October 23, 2026: STAR GROUP ASIA gained 77.49%, MICOT PHARMA-B fell 39.92% and Z.AI led turnover at HK$3.838 billion.
On October 26, 2026, Neautus passed the HKEX listing hearing, ranking second in China's TCM decoction-ready products market with 0.4% in 2025, the top five at 2.7%.
On October 26, 2026, Denglin passed the HKEX listing hearing, ranking third in China enterprise AI GPGPU market by 2025 revenue with a 1.0% share.
On Oct 26, 2026, Csop Hang Seng Tech Index Etf (03033.HK) fell 1.42% to HK$3.744 on turnover of HK$1.45 billion, with AUM of HK$56.4 billion and NAV HK$3.7959.
As of October 26, 2026, CSOP Hang Seng Biotech ETF (03174.HK) rose 0.81% intraday to a latest price of HK$3.488, with a turnover of HK$364,800 and a turnover rate of 0.04%
As of October 26, 2026, Bosera China Reform Hong Kong Central-Soes High Dividend Yield Index Etf(Listed Class) (03437.HK) rose 1.07% intraday to a latest price of HK$9.420, with a turnover of HK$5.199 million and a turnover rate of 0.06%。
On 26 Oct 2026, HUTCHMED (00013.HK) said its SAFFRON trial met its PFS goal, with 7.6 vs 5.4 months (HR 0.55) in MET-driven EGFR-mutant NSCLC.
